PPARs and Metabolic Disorders Associated with Challenged Adipose Tissue Plasticity.
Published version
Peer-reviewed
Repository URI
Repository DOI
Change log
Authors
Abstract
Peroxisome proliferator-activated receptors (PPARs) are members of a family of nuclear hormone receptors that exert their transcriptional control on genes harboring PPAR-responsive regulatory elements (PPRE) in partnership with retinoid X receptors (RXR). The activation of PPARs coordinated by specific coactivators/repressors regulate networks of genes controlling diverse homeostatic processes involving inflammation, adipogenesis, lipid metabolism, glucose homeostasis, and insulin resistance. Defects in PPARs have been linked to lipodystrophy, obesity, and insulin resistance as a result of the impairment of adipose tissue expandability and functionality. PPARs can act as lipid sensors, and when optimally activated, can rewire many of the metabolic pathways typically disrupted in obesity leading to an improvement of metabolic homeostasis. PPARs also contribute to the homeostasis of adipose tissue under challenging physiological circumstances, such as pregnancy and aging. Given their potential pathogenic role and their therapeutic potential, the benefits of PPARs activation should not only be considered relevant in the context of energy balance-associated pathologies and insulin resistance but also as potential relevant targets in the context of diabetic pregnancy and changes in body composition and metabolic stress associated with aging. Here, we review the rationale for the optimization of PPAR activation under these conditions.
Description
Keywords
Journal Title
Conference Name
Journal ISSN
1422-0067
Volume Title
Publisher
Publisher DOI
Sponsorship
Medical Research Council (MC_UU_12012/2)
British Heart Foundation (None)
Medical Research Council (G0600717)
Medical Research Council (G0802051)
Medical Research Council (G0400192)
MRC (MC_UU_00014/2)
MRC (MC_UU_00014/5)
British Heart Foundation (RG/18/7/33636)
Medical Research Council (MC_PC_12012)
Medical Research Council (G0600717/1)